Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company

Saturday, April 26, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

REINACH, Switzerland, April 25 Arpida Ltd.(SWX: ARPN) today announced that Dr Jurgen Raths will succeed Dr Khalid Islamas Chief Executive Officer. Dr Jurgen Raths commands extensive knowledge inthe commercialisation of drugs for the treatment of severe infections inhospitals and has successfully built and lead the European Critical Caresales, medical and marketing organisation of Eli Lilly and Company for manyyears.

At the Annual General Meeting of 7 May, the Board of Directors willpropose to appoint Dr Khalid Islam to the Board of Directors of Arpida Ltd.Dr Islam will work closely with Dr Raths for a seamless transition and willcontinue thereafter as a consultant for the coming years. As a result, hisexperience and expertise in the anti-infective area and his thoroughknowledge of Arpida's programmes will continue to be available to thecompany. Dr Raths, a member of the Arpida board since 2006, will assume hisresponsibilities as CEO on 1 May 2008 focusing during the first two months ondeepening his knowledge of the company and getting to know Arpida'sshareholders and business partners.

Dr Andre Lamotte, Chairman of the Board of Directors of Arpida Ltd.,commented: "Arpida's Board, employees, shareholders and business partners owea lot to Khalid Islam. His outstanding leadership, unwavering energy and deepknowledge have been crucial for Arpida's progress over the past nine years.On behalf of Arpida's Board and staff, I would like to thank Khalid for hisvital contributions. I am very pleased that he will continue to serve Arpidaboth in his function as a board member as well as in his active advisory rolegoing forward. I am particularly delighted and convinced that Jurgen Raths'extensive knowledge of successfully building and managing sales organisationswill enable Arpida to move into the next important phase of becoming a fullyintegrated pharmaceutical company."

Dr Khalid Islam commented, "I am very proud of what we have achieved overthe past nine years. Our key programme iclaprim which started out as an earlypreclinical compound is now under regulatory review. The years ahead willpose new challenges, requiring a different set of skills of a CEO. With thisin mind, I feel it is the right time for a change in leadership at Arpida andto hand over the reigns into the experienced hands of Jurgen Raths. It hasbeen a privilege for me to serve this company during these nine years and Ilook forward to joining Arpida's Board of Directors and to actively supportthe company in its continuing progress."

The nomination of Dr. Khalid Islam to be elected to the Board ofDirectors will be put forward to the Annual General Meeting to take place on7 May 2008 in Basel. With effect as of 1 May 2008, Dr Raths will resign fromthe Board of Directors. The amended invitation is made available on ourwebsite with immediate effect.

About Dr Jurgen Raths

Dr Jurgen Raths studied medicine and dentistry at the Universities ofHeidelberg, Bonn and Cologne. He obtained his MD at the University of Bonn.Since 1990, he held several positions in the global pharmaceutical group, EliLilly and Company, both in Europe and in the US. While at Lilly, he wasinvolved in developing and analysing product portfolio strategies, in productlaunches and the build-up of sales organisations. In August 1999, Dr Rathswas appointed Head Critical Care Europe, the European hospital-focusedbusiness of Eli Lilly and Company. In this function he managed the Europeansales, medical and marketing organisation of approximately 200 people and wasalso responsible for the unit's finance and human resources. During thisassignment he was responsible for the commercialisation of drugs for thetreatment of severe infections (i.e. Xigris). Dr Raths, born 1956, is aGerman citizen, married, with three children, living in Switzerland. He hasbeen on Arpida's Board of Directors since 2006.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store